Cargando…

Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study

BACKGROUND: Primary retroperitoneal sarcoma (RPS) comprises over 70 histologic subtypes, yet there are limited studies that have developed prognostic nomograms for RPS patients to predict overall survival (OS) and cancer-specific survival (CSS). The objective of this study was to construct prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Jialiang, Zhuang, Aobo, Xia, Xiaogang, Miao, Fenglin, Wang, Zhao, Kong, Xu, Ren, Yantao, Ma, Yuan, Lin, Zhenhang, Lu, Weiqi, Li, Wengang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620366/
https://www.ncbi.nlm.nih.gov/pubmed/37910291
http://dx.doi.org/10.1007/s12672-023-00804-1
_version_ 1785130190966358016
author Zheng, Jialiang
Zhuang, Aobo
Xia, Xiaogang
Miao, Fenglin
Wang, Zhao
Kong, Xu
Ren, Yantao
Ma, Yuan
Lin, Zhenhang
Lu, Weiqi
Li, Wengang
author_facet Zheng, Jialiang
Zhuang, Aobo
Xia, Xiaogang
Miao, Fenglin
Wang, Zhao
Kong, Xu
Ren, Yantao
Ma, Yuan
Lin, Zhenhang
Lu, Weiqi
Li, Wengang
author_sort Zheng, Jialiang
collection PubMed
description BACKGROUND: Primary retroperitoneal sarcoma (RPS) comprises over 70 histologic subtypes, yet there are limited studies that have developed prognostic nomograms for RPS patients to predict overall survival (OS) and cancer-specific survival (CSS). The objective of this study was to construct prognostic nomograms for predicting OS and CSS in RPS patients. METHODS: We identified a total of 1166 RPS patients from the Surveillance, Epidemiology and End Results (SEER) database, and an additional 261 cases were collected from a tertiary cancer center. The study incorporated various clinicopathological and epidemiologic features as variables, and prediction windows for overall survival (OS) and cancer-specific survival (CSS) were set at 3, 5, and 7 years. Multivariable Cox models were utilized to develop the nomograms, and variable selection was performed using a backward procedure based on the Akaike Information Criterion. To evaluate the performance of the nomograms in terms of calibration and discrimination, we used calibration plots, coherence index, and area under the curve. FINDINGS: The study included 818 patients in the development cohort, 348 patients in the internal validation cohort, and 261 patients in the external validation cohort. The backward procedure selected the following variables: age, French Federation of Cancer Centers Sarcoma Group (FNCLCC) grade, pre-/postoperative chemotherapy, tumor size, primary site surgery, and tumor multifocality. The validation results demonstrated that the nomograms had good calibration and discrimination, with C-indices of 0.76 for OS and 0.81 for CSS. Calibration plots also showed good consistency between the predicted and actual survival rates. Furthermore, the areas under the time-dependent receiver operating characteristic curves for the 3-, 5-, and 7-year OS (0.84, 0.82, and 0.78, respectively) and CSS (0.88, 0.88, and 0.85, respectively) confirmed the accuracy of the nomograms. INTERPRETATION: Our study developed accurate nomograms to predict OS and CSS in patients with RPS. These nomograms have important clinical implications and can assist healthcare providers in making informed decisions regarding patient care and treatment options. They may also aid in patient counseling and stratification in clinical trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00804-1.
format Online
Article
Text
id pubmed-10620366
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-106203662023-11-03 Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study Zheng, Jialiang Zhuang, Aobo Xia, Xiaogang Miao, Fenglin Wang, Zhao Kong, Xu Ren, Yantao Ma, Yuan Lin, Zhenhang Lu, Weiqi Li, Wengang Discov Oncol Research BACKGROUND: Primary retroperitoneal sarcoma (RPS) comprises over 70 histologic subtypes, yet there are limited studies that have developed prognostic nomograms for RPS patients to predict overall survival (OS) and cancer-specific survival (CSS). The objective of this study was to construct prognostic nomograms for predicting OS and CSS in RPS patients. METHODS: We identified a total of 1166 RPS patients from the Surveillance, Epidemiology and End Results (SEER) database, and an additional 261 cases were collected from a tertiary cancer center. The study incorporated various clinicopathological and epidemiologic features as variables, and prediction windows for overall survival (OS) and cancer-specific survival (CSS) were set at 3, 5, and 7 years. Multivariable Cox models were utilized to develop the nomograms, and variable selection was performed using a backward procedure based on the Akaike Information Criterion. To evaluate the performance of the nomograms in terms of calibration and discrimination, we used calibration plots, coherence index, and area under the curve. FINDINGS: The study included 818 patients in the development cohort, 348 patients in the internal validation cohort, and 261 patients in the external validation cohort. The backward procedure selected the following variables: age, French Federation of Cancer Centers Sarcoma Group (FNCLCC) grade, pre-/postoperative chemotherapy, tumor size, primary site surgery, and tumor multifocality. The validation results demonstrated that the nomograms had good calibration and discrimination, with C-indices of 0.76 for OS and 0.81 for CSS. Calibration plots also showed good consistency between the predicted and actual survival rates. Furthermore, the areas under the time-dependent receiver operating characteristic curves for the 3-, 5-, and 7-year OS (0.84, 0.82, and 0.78, respectively) and CSS (0.88, 0.88, and 0.85, respectively) confirmed the accuracy of the nomograms. INTERPRETATION: Our study developed accurate nomograms to predict OS and CSS in patients with RPS. These nomograms have important clinical implications and can assist healthcare providers in making informed decisions regarding patient care and treatment options. They may also aid in patient counseling and stratification in clinical trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00804-1. Springer US 2023-11-01 /pmc/articles/PMC10620366/ /pubmed/37910291 http://dx.doi.org/10.1007/s12672-023-00804-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Zheng, Jialiang
Zhuang, Aobo
Xia, Xiaogang
Miao, Fenglin
Wang, Zhao
Kong, Xu
Ren, Yantao
Ma, Yuan
Lin, Zhenhang
Lu, Weiqi
Li, Wengang
Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study
title Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study
title_full Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study
title_fullStr Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study
title_full_unstemmed Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study
title_short Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study
title_sort nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620366/
https://www.ncbi.nlm.nih.gov/pubmed/37910291
http://dx.doi.org/10.1007/s12672-023-00804-1
work_keys_str_mv AT zhengjialiang nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT zhuangaobo nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT xiaxiaogang nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT miaofenglin nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT wangzhao nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT kongxu nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT renyantao nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT mayuan nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT linzhenhang nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT luweiqi nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy
AT liwengang nomogramdevelopmentandexternalvalidationforpredictingoverallsurvivalandcancerspecificsurvivalinpatientswithprimaryretroperitonealsarcomaaretrospectivecohortstudy